These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010 [TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449 [TBL] [Abstract][Full Text] [Related]
7. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Benamu E; Montoya JG Curr Opin Infect Dis; 2016 Aug; 29(4):319-29. PubMed ID: 27257797 [TBL] [Abstract][Full Text] [Related]
8. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. Barmettler S; Ong MS; Farmer JR; Choi H; Walter J JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343 [TBL] [Abstract][Full Text] [Related]
9. [Treatment with rituximab as an opportunity for the prevention of infectious complications]. Polák P; Penka M; Smejkal P; Chlupová G Vnitr Lek; 2016; 62(5):398-405. PubMed ID: 27319233 [TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480 [TBL] [Abstract][Full Text] [Related]
11. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931 [TBL] [Abstract][Full Text] [Related]
12. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections. McQuillen DP; Ram S Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552 [No Abstract] [Full Text] [Related]
13. Rituximab and immune deficiency: case series and review of the literature. Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054 [TBL] [Abstract][Full Text] [Related]
14. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531 [TBL] [Abstract][Full Text] [Related]
15. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. Bozio CH; Isenhour C; McNamara LA PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804 [TBL] [Abstract][Full Text] [Related]
17. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. Kim MS; Prasad V JAMA Intern Med; 2020 Feb; 180(2):315-317. PubMed ID: 31657842 [TBL] [Abstract][Full Text] [Related]
18. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904 [TBL] [Abstract][Full Text] [Related]
19. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920 [TBL] [Abstract][Full Text] [Related]
20. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. Szepanowski F; Warnke C; Meyer Zu Hörste G; Mausberg AK; Hartung HP; Kleinschnitz C; Stettner M CNS Drugs; 2021 Nov; 35(11):1173-1188. PubMed ID: 34657228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]